Potent inhibitor of CDK1/cyclin B and GSK-3β
values are 0.4 and 0.23 μ
M respectively). Also inhibits CDK2/cyclin A, CDK2/cyclin E and CDK5/cyclin/p35 (IC50
values are 0.68, 7.5 and 0.85 μ
M respectively). Selective over c-src (IC50
= 15 μ
M), casein kinase 2 (IC50
= 20 μ
M), ERK1 (IC50
= 20 μ
M), ERK2 (IC50
= 9 μ
M) and a range of other protein kinases (IC50
values > 35 μ
M). Generates induced pluripotent stem cells (iPSCs) from somatic cells when used in combination with reprogramming factors; can replace Klf4.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Cell cycle targets in novel anticancer drug discovery.
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Schultz et al.
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Zaharevitz et al.
Cancer Res., 1999;59:2566
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4.
Lyssiotis et al.
The citations listed below are publications that use Tocris products. Selected citations for Kenpaullone include:
Showing Results 1 - 2 of 2